GSK 2830371

GSK2830371是一种口服具有活性的，变构的Wip1 phosphatase抑制剂，IC50为6 nM。 In the PPM1D-amplified MCF7 breast carcinoma cells, GSK2830371 increases the phosphorylation of multiple Wip1 substrates, including p53 (S15), Chk2 (T68), H2AX (S139) and ATM (S1981). GSK2830371 shows selective antiproliferative activity in a subset of lymphoid cell lines, all of which carry a wild-type TP53 allele. Furthermore, co-treatment of doxorubicin and GSK2830371 results in a synergistic antiproliferative effect in DOHH2 and MX-1 tumor cells. In vivo, GSK2830371 increases phosphorylation of Chk2 (T68) and p53 (S15) and decreases Wip1 protein concentrations in DOHH2 tumors. GSK2830371 (150 mg/kg p.o.) also inhibits the growth of DOHH2 tumor xenografts via inhibition of Wip1. GSK2830371是一种口服具有活性的，变构的Wip1 phosphatase抑制剂，IC50为6 nM。

Target	Value
Wip1 phosphatase (Cell-free assay)	6 nM

在PPM1D扩增的MCF7乳腺癌细胞中，GSK2830371增加多重Wip1底物，包括p53 (S15)，Chk2 (T68)，H2AX (S139) 和 ATM (S1981)的磷酸化。GSK2830371在一部分携带野生型TP53等位基因的淋巴样细胞系中表现出选择性抗增殖活性。此外，doxorubicin 和 GSK2830371共处理在DOHH2和MX-1肿瘤细胞中表现出协同的抗增殖作用。

在体内，GSK2830371增加Chk2 (T68) 和 p53 (S15)的磷酸化，并减少DOHH2肿瘤中Wip1蛋白质浓度。GSK2830371 (150 mg/kg p.o.)通过抑制Wip1也会抑制DOHH2肿瘤异种移植物的生长。